These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 4190177)
41. [Drugs in the management of arterial hypertension]. Rev Clin Esp; 1969 Jan; 112(2):207. PubMed ID: 5769042 [No Abstract] [Full Text] [Related]
42. Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension. Rengo F; Ricciardelli B; Volpe M; Trimarco B; Saccà L; Condorelli M Arch Int Pharmacodyn Ther; 1980 Apr; 244(2):281-91. PubMed ID: 6996627 [TBL] [Abstract][Full Text] [Related]
43. Effect of alpha-methyl-dopa (Dopegyt) and other antihypertensive drugs (guanethidine, bethanidine) on the isotope renogram. Radó J; Bános C; Takó J; Szabó T; Borbély L; Szende L; Kapus I; Nagy M Ther Hung; 1969; 17(2):76-82. PubMed ID: 5807612 [No Abstract] [Full Text] [Related]
44. [Studies on the blood pressure lowering effect of cyclazenin and a cyclazenin-alpha-methyldopa combination]. Seige K; Preuss EG; Mörl H; Köhler I; Lantzsch W Med Welt; 1969 Mar; 10():520-6. PubMed ID: 5772239 [No Abstract] [Full Text] [Related]
45. A comparison of alpha-methyldopa (aldomet) and ST155 (catapres) in the treatment of hypertension. Seedat YK; Vawda EI; Mitha S; Ramasar R S Afr Med J; 1970 Mar; 44(10):300-1. PubMed ID: 5443298 [No Abstract] [Full Text] [Related]
46. Epidemiology of stroke: emphasis on transient cerebral ischemia attacks and hypertension. Whisnant JP Stroke; 1974; 5(1):68-70. PubMed ID: 4811314 [No Abstract] [Full Text] [Related]
47. [Complication and prognosis in essential hypertension]. Hiwada K; Imamura Y Nihon Rinsho; 1992 May; 50 Suppl():238-45. PubMed ID: 1387423 [No Abstract] [Full Text] [Related]
48. Therapeutic implications from clinical trials for the treatment of hypertension. Kaplan NM J Clin Hypertens; 1986 Sep; 2(3 Suppl):22S-27S. PubMed ID: 3540225 [No Abstract] [Full Text] [Related]
49. Cerebrovascular events in the Hypertension Detection and Follow-up Program. Daugherty SA; Berman R; Entwisle G; Haerer AF Prog Cardiovasc Dis; 1986; 29(3 Suppl 1):63-72. PubMed ID: 3538180 [No Abstract] [Full Text] [Related]
50. Comparative studies of guanfacine and methyldopa. Roeckel A; Heidland A Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):55S-59S. PubMed ID: 6994779 [TBL] [Abstract][Full Text] [Related]
51. [Controllable hypertension therapy with Tadip]. Schütz E Med Klin; 1971 Jan; 66(4):121-6. PubMed ID: 5546736 [No Abstract] [Full Text] [Related]
55. Diuretics and cerebrovascular outcomes--beyond traditional endpoints. Wijkman M J Clin Hypertens (Greenwich); 2015 Apr; 17(4):273-4. PubMed ID: 25670088 [No Abstract] [Full Text] [Related]
56. Debrisoquine. A five-year study of a new hypotensive agent. Bauer GE Med J Aust; 1970 Nov; 2(20):911-5. PubMed ID: 5486292 [No Abstract] [Full Text] [Related]
57. [Antihypertensive therapy]. Storm-Mathisen H Tidsskr Nor Laegeforen; 1972 Jul; 92(19):1331-7. PubMed ID: 5053651 [No Abstract] [Full Text] [Related]